<qa>  What is the aim of a fixed dose combination of pyronaridine and artePlasmodium falciparum malaria kills over one million people and results in up to 500 million cases annually, affecting mainly young children and pregnant women. Artemisinin-based combination therapies ACT are considered today by WHO to be the best anti-malarials in terms of efficacy and lower propensity to resistance. Pyronaridine artesunate is a new ACT, in development to treat acute uncomplicated malaria. Pyronaridine and artesunate are antimalarial agents with a history of clinical use both separately and in combination with other drugs.Each drug has powerful antischizonticidal actions. The aim of a fixed dose combination of pyronaridine and artesunate in the treatment of uncomplicated acute malaria is to provide rapid reduction in parasitaemia with a three-day regimen, thereby improving compliance and reducing the risk of recrudescence through the slower elimination of pyronaridine. 